Cargando…
Proton pump inhibitor in the prevention of upper gastrointestinal mucosal injury associated with dual antiplatelet therapy after coronary artery bypass grafting (DACAB-GI-2): study protocol for a randomized controlled trial
BACKGROUND: Dual antiplatelet therapy (DAPT) is recommended in secondary prevention after coronary artery bypass grafting (CABG), but it is inevitably associated with the risk of bleeding, of which gastrointestinal bleeding accounts for more than half. Proton pump inhibitors (PPIs) may increase the...
Autores principales: | Zhu, Yunpeng, Wang, Xiaojin, Yang, Yi, Liu, Lei, Zhao, Qiang, Yu, Lifen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287869/ https://www.ncbi.nlm.nih.gov/pubmed/35840999 http://dx.doi.org/10.1186/s13063-022-06464-w |
Ejemplares similares
-
Impact of low-density lipoprotein cholesterol and lipoprotein(a) on mid-term clinical outcomes following coronary artery bypass grafting: A secondary analysis of the DACAB trial
por: Yu, Qixiang, et al.
Publicado: (2023) -
Co-prescription of Dual-Antiplatelet Therapy and Proton Pump Inhibitors: Current Guidelines
por: Saven, Hannah, et al.
Publicado: (2022) -
CYP2C19 genotype and platelet aggregation test-guided dual antiplatelet therapy after off-pump coronary artery bypass grafting: A retrospective cohort study
por: Yao, Haoyi, et al.
Publicado: (2022) -
Proton Pump Inhibitors and Kidney Disease—GI Upset for the Nephrologist?
por: Toth-Manikowski, Stephanie M., et al.
Publicado: (2017) -
Antiplatelet agents and proton pump inhibitors – personalizing treatment
por: Lin, Eugene, et al.
Publicado: (2010)